Cytokine receptor like factor 2 (CRLF2) gene rearrangement in acute lymphoid leukemia (ALL) philadelphia negative Egyptian patients / Hend Sayed Ali ; Supervised Azza Mahmoud Gawish , Wajeet Nabil Sayed , Fatma Abdelelhafiz Mohamed Elrefaey

By:

Hend Sayed Ali

Contributor(s):

Material type: Text

TextLanguage: English Publication details: Cairo : Hend Sayed Ali , 2020Description: 69 P. : charts , facsimiles ; 25cmOther title:

اعادة ترتيب جين شبيه معامل مستقبل السييتوكاين{u٠٦ئ٢}(سى.ار. اف. ال {u٠٦ئ٢} )فى اللوكيميا الليمفاوية الحادة السالبة للفيلادلفيا فى المرضى المصريين [Added title page title]

Subject(s):

Available additional physical forms:

Issued also as CD

Dissertation note: Thesis (M.Sc.) - Cairo University - Faculty of Science - Department of Zoology Summary: Background: Philadelphia chromosome like acute lymphoblastic leukemia (Ph-like ALL) is characterized by a gene expression profile similar to that of Breakpoint cluster region -v-abl Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL1) positive ALL and a poorer outcome. Rearrangements of cytokine receptor ligand factor 2 (CRLF2) are identified in approximately 50% of Ph-like and 10% of B Precursor ALL (B-ALL) patients and represents an unknown oncogenic mechanism in this subset of ALL patients.Objective: To identify the incidence of CRLF2 rearrangement in a cohort of B-ALL adult Egyptian patients who were treated with conventional ALL therapy and to assess its impact on progression free survival (PFS) and over survival (OS) at the National Cancer Institute, Cairo between 2017 to 2019.Patients and Methods: ALL diagnostic work-up was done according to the latest WHO 2016 edition and included Bone marrow (BM) aspiration, immunophenotyping,karyotyping, fluorescent in situ hybridization (FISH) for CRLF2 rearrangements with purinergic receptor P2Y, G-protein coupled, 8 or Immunoglobulin heavy Chain (IGH- CRLF2 or P2RY8-CRLF2).Results: Fifty-Four de novo patients with precursor B-ALL who presented to the National Cancer Institute from 2017 to 2019 (35 males, 19 females). 18.5% of B-ALL Patients recorded CRLF2 rearrangement their median age at diagnosis was 21.5 years (range 18 -59). Median Total leucocytes count (TLC) was 3.35X109/L. Median platelets count was 50.5X109/L (range 24-217). Median Bone Marrow (BM) blasts count was 90%. Median Peripheral Blood (PB) blasts count 77.5%.The progression free survival (PFS) percent in CRLF2 rearrangement patients was 10% and the overall survival (OS) percent was 60 %

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

Holdings
Item type	Current library	Home library	Call number	Copy number	Status	Date due	Barcode
Thesis	قاعة الرسائل الجامعية - الدور الاول	المكتبة المركزبة الجديدة - جامعة القاهرة	Cai01.12.21.M.Sc.2020.He.C (Browse shelf(Opens below))		Not for loan		01010110083956000
CD - Rom	مخـــزن الرســائل الجـــامعية - البدروم	المكتبة المركزبة الجديدة - جامعة القاهرة	Cai01.12.21.M.Sc.2020.He.C (Browse shelf(Opens below))	83956.CD	Not for loan		01020110083956000

Thesis (M.Sc.) - Cairo University - Faculty of Science - Department of Zoology

Background: Philadelphia chromosome like acute lymphoblastic leukemia (Ph-like ALL) is characterized by a gene expression profile similar to that of Breakpoint cluster region -v-abl Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL1) positive ALL and a poorer outcome. Rearrangements of cytokine receptor ligand factor 2 (CRLF2) are identified in approximately 50% of Ph-like and 10% of B Precursor ALL (B-ALL) patients and represents an unknown oncogenic mechanism in this subset of ALL patients.Objective: To identify the incidence of CRLF2 rearrangement in a cohort of B-ALL adult Egyptian patients who were treated with conventional ALL therapy and to assess its impact on progression free survival (PFS) and over survival (OS) at the National Cancer Institute, Cairo between 2017 to 2019.Patients and Methods: ALL diagnostic work-up was done according to the latest WHO 2016 edition and included Bone marrow (BM) aspiration, immunophenotyping,karyotyping, fluorescent in situ hybridization (FISH) for CRLF2 rearrangements with purinergic receptor P2Y, G-protein coupled, 8 or Immunoglobulin heavy Chain (IGH- CRLF2 or P2RY8-CRLF2).Results: Fifty-Four de novo patients with precursor B-ALL who presented to the National Cancer Institute from 2017 to 2019 (35 males, 19 females). 18.5% of B-ALL Patients recorded CRLF2 rearrangement their median age at diagnosis was 21.5 years (range 18 -59). Median Total leucocytes count (TLC) was 3.35X109/L. Median platelets count was 50.5X109/L (range 24-217). Median Bone Marrow (BM) blasts count was 90%. Median Peripheral Blood (PB) blasts count 77.5%.The progression free survival (PFS) percent in CRLF2 rearrangement patients was 10% and the overall survival (OS) percent was 60 %

Issued also as CD

There are no comments on this title.

to post a comment.